Shots:

• The AERISTO study recruited 1-119 patients receiving either Bevespi Aerosphere (7.2/4.8µg) BID via pressurized metered-dose inhaler or umeclidinium/vilanterol (62.5/25µg) QD via dry powder inhaler
• Another P-III PINNACLE study enrolled ~5-000 patients and is performed to test safety and efficacy of Bevespi Aerosphere vs. umeclidinium/vilanterol
•  Bevespi Aerosphere (glycopyrronium/formoterol fumarate) is approved in the US and Canada for COPD with an expected regulatory decision from EU by H2’18

Ref: AstraZeneca | Image: AstraZeneca